Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management is scheduled to present on Monday, January 12, 2026 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast will be available on the company’s Investors website at www.adaptivebiotech.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ADPT declined 1.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: AGIO -2.72%, IDYA -0.77%, TVTX -1.47% versus GLPG +0.9% and TARS +0.42%, suggesting stock-specific trading for ADPT.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Collaboration/licensing | Positive | +1.6% | Two non-exclusive immune receptor licensing agreements with Pfizer in RA. |
| Dec 09 | Investor fireside chat | Neutral | -0.6% | Jefferies fireside chat on MRD and clonoSEQ assay technology. |
| Nov 24 | Clinical data presence | Positive | +9.9% | clonoSEQ MRD featured in <b>89</b> ASH abstracts, including <b>36</b> oral talks. |
| Nov 06 | Investor conferences | Neutral | -5.0% | Planned participation in Jefferies Global Healthcare and Piper Sandler conferences. |
| Nov 05 | Earnings update | Positive | +4.0% | Q3 2025 results with strong MRD growth and raised MRD guidance. |
Stock reactions have been stronger to substantive business or clinical updates (Pfizer deals, ASH data, earnings) than to routine conference participation.
Over the last few months, Adaptive Biotechnologies has reported several notable developments. A Pfizer collaboration and data licensing deal on Dec 15, 2025 coincided with a modest gain. Nearly 89 clonoSEQ abstracts at ASH in late November aligned with a near 10% move. Q3 2025 results on Nov 5 with $94.0M revenue and raised MRD guidance also saw a positive reaction. By contrast, prior conference-participation announcements have had smaller, mixed price responses, similar in nature to today’s JPM conference update.
Market Pulse Summary
This announcement highlights Adaptive Biotechnologies’ upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. In recent months, the stock reacted more meaningfully to business updates like the Pfizer agreements and Q3 results with $94.0M revenue and raised MRD guidance. Investors following this news may focus on what new qualitative or quantitative details management shares at the conference relative to those prior milestones.
AI-generated analysis. Not financial advice.
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) present at the J.P. Morgan Healthcare Conference?
How can investors watch the Adaptive Biotechnologies (ADPT) presentation on January 12, 2026?
What topics will Adaptive Biotechnologies (ADPT) cover at the January 2026 presentation?
Is the Adaptive Biotechnologies (ADPT) presentation at J.P. Morgan open to the public?
Will a replay of Adaptive Biotechnologies (ADPT) presentation from January 12, 2026 be available?
